Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (symbol: SENS) is a pioneering medical technology firm based in Germantown, Maryland. The company's primary focus is on developing and commercializing advanced glucose monitoring systems that significantly improve the lives of people managing diabetes. Utilizing cutting-edge fluorescence sensing technology, Senseonics has designed the Eversense Continuous Glucose Monitoring (CGM) System, recognized for being the first fully implantable CGM system. This system comprises a tiny sensor implanted under the skin, an external smart transmitter, and a user-friendly mobile application, allowing for real-time glucose monitoring without the need for a dedicated receiver.
The Eversense CGM System stands out for its accuracy and stability throughout its extended sensor life, offering continuous glucose monitoring for up to 180 days. This long-term solution provides an alternative to traditional short-term CGMs, catering to individuals who require a more stable and reliable glucose monitoring option.
Senseonics has established strong partnerships, including a notable collaboration with Ascensia Diabetes Care, which ensures that their innovative solutions reach a global audience. Their latest product, the Eversense E3 CGM System, is part of an extended assistance program known as the Eversense Payment Assistance and Simple Savings (PASS) Program. This program offers eligible individuals in the U.S. the opportunity to access the Eversense E3 systems at a significantly reduced out-of-pocket cost of $99 for each six-month period, thereby making continuous glucose monitoring more affordable.
Senseonics is committed to advancing diabetes management technology, as evidenced by their continued innovation and dedication to improving accessibility to their products. The company's forward-looking approach and strategic alliances position them as a key player in the medical technology landscape, specifically in the context of diabetes management.
Senseonics Holdings, Inc. (NYSE American: SENS) announced updates regarding their next-generation Eversense 180-day continuous glucose monitoring (CGM) system. The FDA's review for the PMA supplement is nearing completion, with a decision expected soon. The company is working with Ascensia Diabetes Care to ensure a smooth transition to the new system, including marketing campaigns and reimbursement plans. Senseonics maintains its revenue outlook for 2021, projecting net revenues between $12 million and $15 million.
Senseonics Holdings, Inc. (SENS) announced the receipt of the CE mark for its Eversense NOW Remote Monitoring App for Android, enhancing its long-term continuous glucose monitoring system. The app, which offers real-time glucose data monitoring for users and their families, is expected to launch in Q1 2022. The Eversense XL CGM System allows glucose measurement for up to 180 days. The company emphasizes its commitment to transforming diabetes management with innovative technology.
Senseonics Holdings, Inc. (SENS) reported third quarter 2021 revenue of $3.5 million, a significant increase from $0.8 million in Q3 2020. U.S. revenue was $0.6 million, while international sales reached $2.9 million. The net income surged to $42.9 million or $0.10 per share, a turnaround from a net loss of $23.4 million a year prior. However, the company anticipates 2021 global net revenue to fall within $12 million to $15 million due to uncertainties related to COVID-19 and FDA reviews.
Senseonics Holdings, Inc. (AMEX: SENS) has announced participation in two upcoming investor conferences. Management will engage in a virtual fireside chat on November 16, 2021, at 8:40am ET during the Stifel 2021 Virtual Healthcare Conference. Additionally, a presentation will be available on November 18, 2021, at 3:00am ET at the Jefferies London Healthcare Conference. Interested parties can access live and on-demand webcasts on the Company’s website. Senseonics focuses on long-term glucose monitoring systems for diabetes management.
Senseonics Holdings, Inc. (AMEX: SENS) has announced plans to release its third quarter 2021 financial results on November 9, 2021, after market close. A conference call will be held at 4:30 p.m. Eastern Time to discuss the company's performance for the quarter. Investors can access the webcast through Senseonics' website. The company specializes in developing long-term, implantable continuous glucose monitoring systems aimed at improving diabetes management.
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants under its 2019 Inducement Plan to 11 new non-executive employees as of October 1, 2021. A total of 74,000 non-qualified stock options were granted at an exercise price of $3.45 per share, the closing price on the grant date. The options vest 25% on the first anniversary of employment, with the remainder vesting monthly over three years, dependent on continued service. Senseonics aims to expand its Eversense Continuous Glucose Monitoring (CGM) System for diabetes management.
The University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio, has commenced offering the Eversense® Continuous Glucose Monitoring (CGM) System to Medicare enrollees as of early September 2021. This initiative aims to improve diabetes management among patients with type 1 and type 2 diabetes who are on insulin. The Eversense CGM System, which features a long-term implantable sensor and a smart transmitter, enhances patient experience and supports better health outcomes, as emphasized by Betul Hatipoglu, M.D. at UHACO.
Senseonics Holdings, Inc. (NYSE American: SENS), specializing in long-term, implantable continuous glucose monitoring systems, plans to participate in the virtual H.C. Wainwright Global Investment Conference. Management will engage in one-on-one meetings on September 15, 2021, with a presentation webcast available starting September 13, 2021, at 7:00 AM ET. Access to the on-demand webcast will be provided on the company’s website. Senseonics is dedicated to transforming diabetes management with its Eversense® CGM products, which offer real-time glucose data via a mobile app.
Senseonics Holdings reported second quarter 2021 revenue of $3.3 million, significantly up from $0.26 million in Q2 2020. U.S. revenue was $0.98 million, while international revenue reached $2.31 million. The company raised $50 million through an equity offering, mainly for debt service. However, net loss expanded to $180.32 million or $0.42 per share, largely due to increased accounting charges. Senseonics projects 2021 global net revenue between $12 million to $15 million.
Senseonics Holdings, Inc. (NYSE-American: SENS) has announced its plan to release second quarter 2021 financial results on August 9, 2021, after market close. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss its performance, with a concurrent webcast available on their website. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems, such as the Eversense and Eversense XL, which provide real-time glucose data to users via a smartphone app.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
What does Senseonics Holdings, Inc. specialize in?
What is the Eversense Continuous Glucose Monitoring (CGM) System?
How long can the Eversense CGM System monitor glucose levels?
What is the Eversense Payment Assistance and Simple Savings (PASS) Program?
How does Senseonics' CGM technology benefit people with diabetes?
Where is Senseonics Holdings, Inc. headquartered?
Who are Senseonics' key partners?
How can I learn more about the Eversense CGM System?
Is the Eversense CGM System available outside the United States?
What is the mission of Senseonics Holdings, Inc.?
